Senolytic Therapy Enabled by Senescent Cell‐Sensitive Biomimetic Melanin Nano‐Senolytics
Advanced Healthcare Materials · 2024
DOI: 10.1002/adhm.202401085 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Healthcare Materials, 2024. Verfasst von Hairui Zhang und 10 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Artificial Organs and Computational Medicine, Institute of Translational Medicine, Zhejiang Shuren University, Hangzhou, Zhejiang, …. Hauptthemen laut MEDLINE: Cellular Senescence, Nanoparticles, Senotherapeutics. Die Arbeit wurde bisher 28-mal zitiert (Crossref) und nennt 76 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Key Technologies Research and Development Program, National Key Scientific Instrument and Equipment Development Projects of China.
Abstract (Originalsprache)
Cellular senescence is a significant risk factor for aging and age‐related diseases (ARD). The canonical senolytics Dasatinib and Quercetin (DQ) have shown promise in clearing senescent cells (SnCs); however, the lack of selectivity poses a challenge in achieving optimal outcomes. Despite the recent occurrence of nanomaterial‐based approaches targeting SnCs, limited therapeutic effects, and potential toxicity still remain a major concern. Herein, a “double locks‐like” nanoplatform is developed that integrated Galactan coating and mesoporous polydopamine to encase the senolytic drug DQ. By this way, DQ is only released in SnCs that are featured with higher levels of β‐galactosidase (β‐gal) and low PH. Additionally, the nanoparticles are equipped with 2,2,6,6‐Tetramethylpiperidine‐1‐oxyl (Tempo) to gain enhanced photothermal converting potential. Consequently, the synthesized nanosenolytics demonstrate remarkable specificity and efficacy in eradicating SnCs, and accordingly reverse pulmonary fibrosis in mice without affecting normal tissues. Upon exposure of near‐infrared (NIR) light, the nanoparticles demonstrate to efficiently remove senescent tumor cells inducted by chemotherapy, thereby hindering the outgrowth and metastasis or breast cancer. Collectively, the present study develops an “On/Off” switchable nanoplatform in response to SnCs, and produces a more safe, efficient, and feasible way to delay aging or alleviate age‐associated diseases.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Key Laboratory of Artificial Organs and Computational Medicine, Institute of Translational Medicine, Zhejiang Shuren University, Hangzhou, Zhejiang, 310015, China.
- School of Pharmaceutical Sciences, Zhejiang Chinese Medical University, Hangzhou, 310053, China.
- Shulan International Medical College, Zhejiang Shuren University, Hangzhou, 310015, China.
- Department of Immunology and Medical Microbiology, Nanjing University of Chinese Medicine, Nanjing, 210046, China.
- College of Basic Medical Science, Zhejiang Chinese Medical University, Hangzhou, 310053, China.
ORCID-Profile: Xiaoling Xu, Liyun Shi
Förderung
- Key Technologies Research and Development Program
- National Key Scientific Instrument and Equipment Development Projects of China
Zitieren
APA
Zhang, H., Xu, X., Shou, X., Liao, W., Jin, C., Chen, C., Zhang, C., Gao, W., Zhang, J., Ge, W., & Shi, L. (2024). Senolytic Therapy Enabled by Senescent Cell‐Sensitive Biomimetic Melanin Nano‐Senolytics. Advanced Healthcare Materials. https://doi.org/10.1002/adhm.202401085
Vancouver
Zhang H, Xu X, Shou X, Liao W, Jin C, Chen C, et al. Senolytic Therapy Enabled by Senescent Cell‐Sensitive Biomimetic Melanin Nano‐Senolytics. Advanced Healthcare Materials. 2024. doi:10.1002/adhm.202401085
BibTeX
@article{Zhang2024,
author = {Zhang, Hairui and Xu, Xiaoling and Shou, Xin and Liao, Wucan and Jin, Chengkang and Chen, Changjiang and Zhang, Chen and Gao, Wenhua and Zhang, Junfeng and Ge, Weihong and Shi, Liyun},
title = {Senolytic Therapy Enabled by Senescent Cell‐Sensitive Biomimetic Melanin Nano‐Senolytics},
journal = {Advanced Healthcare Materials},
year = {2024},
doi = {10.1002/adhm.202401085}
}
EUVIMED